Interchange Capital Partners’s AstraZeneca AZN Stock Holding History

Interchange Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$304K	Buy	+1,617	New	+$304K	0.06%	293
2026 Q1	–	Sell	-1,947	Closed	-$358K	–	320
2025 Q4	$358K	Buy	1,947 +339	+21%	+$59.5K	0.07%	260
2025 Q3	$247K	Buy	+1,608	New	+$243K	0.05%	308
2024 Q4	–	Sell	-1,504	Closed	-$235K	–	269
2024 Q3	$235K	Sell	1,504 -36	-2%	-$5.81K	0.08%	234
2024 Q2	$240K	Buy	+1,540	New	+$232K	0.09%	229
2021 Q1	–	Sell	-954	Closed	-$95K	–	304
2020 Q4	$95K	Buy	+954	New	+$101K	0.05%	312

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Interchange Capital Partners's AZN Position: Q2 2026 in Review

Interchange Capital Partners opened a new position in AstraZeneca (AZN) in Q2 2026: 1,617 shares worth $304K. The stake represents 0.06% of the portfolio and ranks #293 among its holdings. This is a return to the name: Interchange Capital Partners previously reported a position in AZN as recently as Q4 2025.

Interchange Capital Partners first reported a position in AZN in Q4 2020 and has held it in 6 quarters since. The position peaked at $358K in Q4 2025. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Interchange Capital Partners held 1,617 shares of AstraZeneca worth $304K as of Q2 2026.
AstraZeneca was a new Interchange Capital Partners position in Q2 2026.
AstraZeneca made up 0.06% of Interchange Capital Partners's portfolio in Q2 2026, its #293 holding.
Interchange Capital Partners first reported a position in AstraZeneca in Q4 2020 and has held it in 6 quarters since.
Interchange Capital Partners's AstraZeneca position peaked at $358K in Q4 2025.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Interchange Capital Partners's 13F filing for Q2 2026, filed 20 Jul 2026.